Exagen Inc. (NASDAQ: XGN) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $105M. The Maz Rating grades it against the other companies in its sector.
Exagen Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.13, Exagen Inc. trades at 1.5x sales and 7.5x book value. Over the last twelve months it generated about $72M of revenue and a net loss of $19M. It runs a gross margin of 58.7%, an operating margin of -20.1% and a net margin of -25.1%. It shows return on equity of -125.6%, return on invested capital of -32.5% and a free cash flow yield of -12.4%. On the balance sheet: a debt-to-equity ratio of 2.09 and a current ratio of 3.46. Over the past 52 weeks the share price ranged from $2.59 to $9.22, with a beta of 2.12.
Exagen Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 10 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.